WO2001038330A1 - Cristaux de mirtazapine anhydres et leur procede de fabrication - Google Patents
Cristaux de mirtazapine anhydres et leur procede de fabrication Download PDFInfo
- Publication number
- WO2001038330A1 WO2001038330A1 PCT/JP2000/006687 JP0006687W WO0138330A1 WO 2001038330 A1 WO2001038330 A1 WO 2001038330A1 JP 0006687 W JP0006687 W JP 0006687W WO 0138330 A1 WO0138330 A1 WO 0138330A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- mirtazapine
- crystals
- water
- hydrate
- crystal
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Definitions
- the present invention relates to anhydrous mirtazapine crystals and a method for producing the same, and mirtazapine hydrate crystals and a method for producing the same. More specifically, the present invention relates to an anhydrous mirtazapine crystal having low hygroscopicity useful as an antidepressant and a method for producing the same, and a crystal of mirtazapine hydrate useful as an intermediate for producing the anhydrous miruzapine crystal and a method for producing the same.
- the crystals of the mill zapine have the disadvantage that they cannot be handled and stored under dry conditions because they have a hygroscopic property.
- An object of the present invention has been made in view of the above prior art, and is a method capable of efficiently producing high-purity mirtazapine from crude mirtazapine, and an anhydrous mirtazapine crystal having low hygroscopicity, a method for producing the same, and the anhydrous Mirtazapine crystal
- An object of the present invention is to provide mirtazapine hydrate crystals useful as a production intermediate and a method for producing the same. Disclosure of the invention
- a low-hygroscopic anhydrous mirtazapine crystal having a moisture absorption of 0.6% by weight or less when stored in air at 25 ° C and a relative humidity of 75% under the atmospheric pressure for 500 hours;
- Mirtazapine hydrate crystals are dried, and have a moisture absorption of 0.6 weight when stored in air at 25 ° C and 75% relative humidity under atmospheric pressure for 500 hours. %, A method for producing low-hygroscopic anhydrous mirtazapine crystals of
- Equation (3) Equation (3)
- n an integer of 1 to 5
- FIG. 1 is a view showing an infrared absorption spectrum of a crystal of mirtazapine hydrate obtained in Example 1 of the present invention.
- FIG. 2 shows the anhydrous mirtazapine crystals obtained in Example 7 and Comparative Example 3 of the present invention.
- FIG. 4 is a diagram showing a change over time in the amount of water absorption of the present invention.
- FIG. 3 is an X-ray diffraction pattern of mirtazapine hydrate crystals obtained in Example 8 of the present invention.
- FIG. 4 is a molecular structure diagram of mirtazapine hydrate crystals obtained in Example 8 of the present invention.
- FIG. 5 is a crystal structure diagram in the a-axis direction of mirtazapine hydrate crystals obtained in Example 8 of the present invention.
- FIG. 6 is a crystal structure diagram in the b-axis direction of the crystals of milza zapine hydrate obtained in Example 8 of the present invention.
- FIG. 7 is a c-axis crystal structure diagram of mirtazapine hydrate crystals obtained in Example 8 of the present invention.
- FIG. 8 is an X-ray diffraction diagram of the anhydrous mirtazapine crystal obtained in Example 10 of the present invention.
- FIG. 9 is a micrograph of particles when the anhydrous mirtazapine crystal obtained in Example 9 of the present invention was pulverized.
- FIG. 10 is a photomicrograph of particles when the anhydrous mirtazapine crystal obtained in Example 9 of the present invention was pulverized and dried.
- anhydrous in anhydrous mirtazapine crystals means that the mirtazapine crystals are substantially free of moisture. More specifically, the water content of the anhydrous millapine crystals is preferably 0.5% by weight or less, more preferably 0.3% by weight or less, from the viewpoint of imparting sufficient low moisture absorption.
- the low-hygroscopic anhydrous mirtazapine crystal of the present invention has a moisture absorption of 0.6% by weight or less when stored for 50 hours under atmospheric pressure in air at 25 ° C. and a relative humidity of 75%. This facilitates the handling and formulation of crystals, and improves storage stability.
- mirtazapine hydrate crystals can be used as a starting compound for anhydrous mirtazapine crystals.
- the crystal of mirtazapine hydrate has the formula (I):
- n an integer of 1 to 5
- n is preferably 2 or 3. Above all, n is 2, that is, a crystal of mirtazapine monophosphate dihydrate is preferable from the viewpoint of crystallinity, handleability, and storage stability.
- This crystal of mirtazapine 1Z dihydrate has a unique diffraction peak when the diffraction angles (20) are 9.28, 14.36, 20.46 and 26.92 in X-ray diffraction. Things.
- the crystal of mirtazapine hydrate can be easily prepared as follows, for example, by using crude mirtazapine as a starting material. The crude mirtazapine has a purity of about 99% or less and can be prepared, for example, by the method described in US Pat. No. 4,062,848.
- the crude mirtazapine used in the present invention is a solution of 2 g of crude milled zapine in 1 OmL of methanol, and absorbance at a wavelength of 600 nm and wavelength of 400 nm in a 1 Omm quartz cell.
- the absorbance at a wavelength of 600 nm was 0.1 or more, and the transmittance at a wavelength of 400 nm was measured using a measuring device (UV-2500 PC, manufactured by Shimadzu Corporation).
- UV-2500 PC manufactured by Shimadzu Corporation
- the transmittance at 30 nm is 30% or less, and the color is measured with a color difference meter (Z-30 OA, color difference meter manufactured by Nippon Denshoku Industries Co., Ltd.) It means that the b value in the difference meter is 10 or more.
- the solvent examples include lower alcohols such as methanol and ethanol; ethers such as dioxane and tetrahydrofuran; ketones such as acetone; esters such as methyl acetate; non-protonic organic solvents such as dimethylformamide and dimethylsulfoxide. And a mixed solvent of water and a water-soluble organic solvent.
- lower alcohols such as methanol and ethanol are preferred.
- the amount of water relative to 100 parts by weight of the water-soluble organic solvent is from 50 to 200 parts by weight, preferably from 80 to 100 parts by weight, from the viewpoint of improving the yield and the purity and hue. It is desirably 0 parts by weight.
- the amount of the solvent is usually 50 to 300 parts by weight, preferably 50 to 200 parts by weight, based on 100 parts by weight of mirtazapine, from the viewpoint of improving the yield and improving the purity and hue. It is desirable that the amount be 100 parts by weight, more preferably 100 to 100 parts by weight.
- the temperature at which the crude mirtazapine is dissolved in the solvent is not particularly limited, but is usually from 0 to 80, preferably from 0 to 60, from the viewpoint of precipitating impurities as insoluble materials and efficiently removing them. It is more preferable that the temperature be 0 to 10 ° C.
- the crude mirtazapine obtained by dissolving the crude mirtazapine in the solvent is used. It is preferable to add water to the mirtazapine solution.
- the amount of water is preferably about 100 to 100 parts by weight with respect to 100 parts by weight of the solvent from the viewpoint of improving purity and hue.
- decolorizing carbon may be appropriately added to the crude mirtazapine solution.
- the amount of the decolorizing carbon used is preferably about 0.5 to 10 parts by weight based on 100 parts by weight of crude mirtazapine from the viewpoint of improvement in purity and hue.
- a crude mirtazapine solution containing the decolorized carbon was added. It is preferable to stir the solution at a temperature of 0 to 70 ° C, preferably about 0 to 30 ° C for 10 to 60 minutes.
- the decolorized carbon is filtered off, and the decolorized carbon is washed with a water-soluble organic solvent such as methanol, ethanol, dioxane, tetrahydrofuran, acetone, methyl acetate, dimethylformamide, and dimethyl sulfoxide, and the crystal form is removed.
- a water-soluble organic solvent such as methanol, ethanol, dioxane, tetrahydrofuran, acetone, methyl acetate, dimethylformamide, and dimethyl sulfoxide, and the crystal form is removed.
- water is dropped into the obtained mill zapine solution in an amount of about 100 to 100 parts by weight with respect to 100 parts by weight of the crude mill zapine. Is preferred. Thereafter, the obtained solution is cooled to a temperature of about 0 to 5 ° C, and a seed crystal of mirtazapine hydrate may be added to the solution to make the crystal form uniform.
- the amount of the seed crystal is not particularly limited, but may be about 0.05 to 1 part by weight based on 100 parts by weight of crude mirtazapine.
- the crystals of the obtained mirtazapine hydrate are collected by filtration, if necessary, the crystals are washed with, for example, a water-soluble organic solvent such as methanol or ethanol, water, or a mixed solvent of the water-soluble organic solvent and water. And then dried. Thus, crystals of mirtazapine hydrate are obtained.
- the average particle size of the obtained mirtazapine hydrate crystals is usually 60 to 150 m, but if necessary, it may be pulverized with a pulverizer such as a hammer mill.
- An anhydrous mirtazapine crystal having low hygroscopicity can be easily produced by drying mirtazapine hydrate crystals obtained by crystallization from a water-containing solvent as described above.
- This anhydrous mirtazapine crystal has a diffraction angle (20) force of 9.14, 9.38, 14.16, 18.46, 18.8.56, and 20.80 in X-ray diffraction. When it is 56, it has a unique diffraction peak.
- the mirtazapine hydrate crystals Before drying the mirtazapine hydrate crystals, it is preferable to pulverize the mirtazapine hydrate crystals so that the drying can be performed efficiently. This pulverization is performed after filtering the generated crystals of mirzapine hydrate, but in order to efficiently pulverize the crystals of mirzapine hydrate, the crystals of the mirtazapine hydrate are preliminarily prepared. Drying is preferred. Predrying can be performed by heating the crystals of mirtazapine hydrate to a temperature of 40 to 80 for about 1 to 6 hours.
- Crushing can be performed using a crusher such as a hammer mill, a cutter mill, and an atomizer.
- the pulverization is desirably carried out so that the average particle size of the millapine hydrate crystals after the pulverization is about 10 to 70, preferably about 20 to 60 m.
- the average particle diameter was measured by using SALD 110, manufactured by Shimadzu Corporation, water as a medium, and Triton X—100 (ROHM) as a dispersant.
- the heating temperature is from 70 to 110 ° C, preferably from 85 to 110 ° C, more preferably from 9 to 110 ° C from the viewpoint of shortening the drying time and avoiding deterioration of mirtazapine hydrate. It is desirable that the temperature be 0 to 105 ° C.
- the drying time can be further reduced.
- the degree of decompression is 1.33 to 13300 Pa, preferably 10 to 650 Pa, and more preferably. Is desirably 100 to 1995 Pa.
- the drying of the crystals of mirtazapine hydrate is carried out until the water content of the obtained anhydrous mirtazapine crystals becomes 0.5% by weight or less, preferably 0.3% by weight or less. It is desirable from the viewpoint of imparting low hygroscopicity.
- the mirtazapine crystals thus obtained have an exceptional moisture absorption of 0.6% by weight or less even when stored in air at 25 ° C and a relative humidity of 75% under atmospheric pressure for 500 hours. It exhibits remarkably excellent properties.
- low-hygroscopic anhydrous mirtazapine crystals can be easily produced on an industrial scale, starting from mirtazapine hydrate crystals.
- the obtained reaction mixture was added dropwise into a 1-L flask charged with 258.8 g of water, and then the inside of the flask was washed with 28.8 g of water. Next, the pH of the reaction mixture was adjusted to about 8 with a 25% aqueous sodium hydroxide solution, decolorized with 1.9 g of decolorizing carbon, filtered, and washed with 38 g of water.
- Example 1 71 g of mirtazapine hydrate obtained in Example 1 was dissolved in 356 g of tert-butyl methyl ether at 50 ° C., and water and tert-butyl methyl ether were added at a temperature of 55 ° C. under normal pressure. Was azeotropically dehydrated, and 255.3 g of tert-butyl methyl ether was distilled off. Next, the solution was cooled to 0-5 ° C, aged for 30 minutes, and filtered. The obtained crystals were washed with 52 g of cold tert-butyl methyl ether (about 0 to 5 ° C.) and dried to obtain 52 g of mirtazapine in white. The HP LC purity of the milled zapine was 99.9%.
- Example 3 5 g of mirtazapine hydrate obtained in Example 1 was pre-dried under reduced pressure at 55 ° C. for 2 hours. The water content was 2.6% by weight.
- the pre-dried mirtazapine hydrate was pulverized in a mortar, and the average particle diameter [measurement device: S ALD 110, manufactured by Shimadzu Corporation, medium: water, dispersant: Triton X -100 (measured by Rohm and Haas Co., Ltd., trade name).
- the powder was dried at 90 ° C under a reduced pressure of 133,3 Pa for 6 hours, and the water content was 0.4% by weight.
- the average particle size of the powder after drying was 41.2 tzm.
- Millite zapine hydrate 5 obtained in Example 1 was pre-dried under reduced pressure at 55 ° C. for 2 hours.
- the water content was 2.8% by weight.
- the pre-dried mirtazapine hydrate was pulverized in a mortar to obtain a powder having an average particle diameter of 52.87 m.
- Example 2 5 g of mirtazapine hydrate obtained in Example 1 was pre-dried under reduced pressure at 55 for 2 hours. The water content was 2.7% by weight.
- the pre-dried mirtazapine hydrate was pulverized in a mortar to obtain a powder having an average particle diameter of 47.7 m.
- the powder was dried at 90 ° C under a reduced pressure of 133,3 Pa for 4 hours to obtain a water content of 0.4% by weight, and further dried for 3 hours to obtain a water content of 0.227% by weight.
- the average particle size of the powder after drying was determined to be 110.4 m.
- the obtained product was analyzed by high performance liquid chromatography (hereinafter referred to as HPLC), and as a result, 98.1% of mirtazapine was formed in the reaction solution.
- HPLC high performance liquid chromatography
- 8660 g of water was added dropwise at 0 to 5 ° C, and 1397 g of water was further added.
- a solution prepared by dissolving 3143 g of sodium hydroxide in 9428 g of water was added dropwise at a temperature of 30 ° C. or lower to adjust the pH to 1-2.
- the reaction solution was decolorized by adding 67 g of decolorizing carbon at 20-30 ° C., filtered, and filtered with water.
- the decolorized charcoal was washed with 1 330 g.
- the filtrate was washed by adding 2095 g of toluene, the toluene layer was separated, 2095 g of toluene was added to the aqueous layer, and then a solution prepared by dissolving 936 g of sodium hydroxide in 2810 g of water was added.
- the solution was dropped at a temperature of 50 ° C. or less to adjust the pH to 8 or more. Thereafter, liquid separation was performed at 75 to 80 ° C., and the organic layer was separated.
- heptane (20995 mL) was added dropwise to the organic layer at 50 to 60 ° C to precipitate crystals, which were cooled to 0 to 5 ° C and then aged for 1 hour. After filtration, 160 mL of toluene and 160 mL of heptane were mixed, and the crystals were washed with a liquid cooled to 0 to 5 ° C.
- Crude mirtazapine [absorbance at a wavelength of 600 nm: 2.4154] The transmittance at a wavelength of 400 nm was 0.01%, and the b value of the color difference meter was 22.0].
- the solution was cooled at 0 to 5 ° C for 1 hour, filtered, and mixed with 43.2 mL of methanol and 129.6 mL of ion-exchanged water at a temperature of 0 to 5 ° C.
- the crystals were washed.
- the crystals are dried at 60 ° C and the crystals of mirtazapine 1 Z2 hydrate 1 2 1.
- Example 6 The crystals of mirtazapine 1 dihydrate obtained in Example 6 were dried at 90 to 95 ° C. under a reduced pressure of 133 to 1862 Pa. The water content of the obtained anhydrous mirtazapine crystal was measured by the Karl'Fisher method and found to be 0.1% by weight. Its melting point was 114 ° C to 116 ° C. Comparative Example 3
- the crude mirtazapine obtained in Production Example 1 was recrystallized according to the method described in US Pat. No. 4,062.848. That is, 20 g of the crude mirtazapine obtained in Production Example 1 was dissolved by heating in 140 mL of tert-butyl methyl ether, 0.2 g of decolorizing carbon and 0.2 g of celite were added, and the mixture was decolorized and filtered. The mixture was concentrated until the amount became 41.2 g, 5.4 g of tert-butyl methyl ether was added thereto, and the mixture was cooled to 3 ° C. for crystallization. Thereafter, the mixture was filtered and dried at 50 ° C. to obtain 16.5 g of mirtazapine crystals.
- the obtained mirtazapine crystals were dried at 90 to 95 ° C under a reduced pressure of 1330 to 1995 Pa, and the water content was measured by Karl Fischer method. It was a target.
- Example 7 the mirtazapine crystals obtained in Example 7 and Comparative Example 3 were placed in a petri dish, placed in a thermostatic chamber having a relative humidity of 75% and a room temperature of 25 ° C, and the change in the amount of absorbed moisture of the crystals was examined.
- Fig. 2 shows the results.
- the amount of moisture absorption is calculated by the formula:
- Example 8 From the results shown in FIG. 2, the anhydrous mirtazapine crystals obtained in Example 7 showed a much higher moisture absorption after elapse of 500 hours compared to the miruzazapine crystals obtained in Comparative Example 3. It can be seen that they are extremely low and have extremely low hygroscopicity.
- Example 8
- the mixture was stirred at 0 to 5 ° C for 1 hour, and the crystals were filtered, and washed with a mixed solution of 350 g of methanol and 1291 g of ion-exchanged water (liquid temperature: 0 to 5 ° C). Dry under reduced pressure (4 to 5.3 kPa) at 50 to 60 ° C until the water content becomes 3.5% by weight or less, pulverize with a pulverizer (hammer mill), and obtain an average particle diameter of 20 im. A crystal of zapine hydrate was obtained.
- Crystal parameters were determined based on the results of X-ray diffraction. The results are as follows.
- Table 1 shows the atomic coordinates, isotropic temperature factor and occupancy
- Table 2 shows the anisotropic temperature factor
- Table 3 shows the interatomic (bond) distance
- Table 4 shows the bond angle
- Table 5 shows the twist angle .
- FIG. 4 shows a molecular structure diagram of the mill azapine hydrate obtained in Example 8.
- FIGS. 5, 6, and 7 show the crystal structure diagrams of the mill azapine hydrate obtained in Example 8 in the a-axis direction, the b-axis direction, and the c-axis direction, respectively.
- the space group of the crystal of mirtazapine hydrate obtained in Example 8 was P 2, Z, which has a center of symmetry and is found to exist in a racemic form.
- the position of the oxygen atom in the water molecule was estimated from the electron density distribution. Examination of the electron density distribution revealed that there were positions with a high probability of existence at two force points near the center of symmetry. This distance is 1.75 A. Compared to the van der Waals radius of oxygen atoms of 1.4 A, it is considered that two oxygen atoms exist at a distance of 1.75 A. It is difficult. Therefore, it is presumed that the oxygen atoms of the water molecule do not exist simultaneously in these two places, but in one of the two places in a random (probably temporal) manner. You.
- Example 8 The mill zapine hydrate obtained in Example 8 was dried in an atmosphere at 50 to 60 ° C. for 17 hours, and its water content became 2.2%. In addition, an atmosphere of 85-95 ° C After drying in an atmosphere for 23 hours, anhydrous mirtazapine crystals (average particle size: 118 m) having a water content of 0.58% were obtained.
- FIG. 9 shows a micrograph (magnification: X200) of the obtained crystal.
- FIG. 10 shows a micrograph (magnification: X200) of the obtained crystal after drying.
- the crystals of the mill zapine hydrate obtained in Example 8 were dried at a temperature of 85 to 105 ° C. under a reduced pressure of 600 to 1333 Pa, and 6 hours from the start of drying. 99.5 g of anhydrous mirtazapine crystal having a water content of 0.46% by weight and a water content after 10 hours of 0.3% by weight were obtained.
- the physical properties of the obtained anhydrous mirtazapine crystal are as follows.
- the obtained crystals were washed with a mixture of methanol (21.6 kg) and ion-exchanged water (81.2 kg) (liquid temperature: 2.6 ° C) to obtain wet crystals (83.9 kg). It was dried at 60-95 ° C. for 11 hours under reduced pressure of 26 66-53 33 Pa to obtain 72.5 kg of mirtazapine hydrate. The yield was 89.5%.
- the obtained crystals were pulverized with an atomizer. 54.3 kg of the crushed crystals were further dried under a reduced pressure of 133 to 400 Pa at 90 to 95 ° C for 7 hours to obtain 52.5 kg of anhydrous mirtazapine.
- the purity of the crystals of the anhydrous mirtazapine was 99.997%.
- the average particle size of the obtained crystals was 25.5 ⁇ m, and the bulk density was 0.27 gZmL for dynamic and 0.51 gZmL for static.
- the absorbance at a wavelength of 600 nm was 0.0048
- the transmittance at a wavelength of 400 nm was 98.84%
- the b value of the color difference meter was 2.42.
- the manufacturing method of this invention the effect that the hygroscopic property and the stable anhydrous mill zapine crystal can be manufactured by a simple industrial method is produced. Further, since the anhydrous mirtazapine crystal of the present invention has excellent low hygroscopicity, it can be suitably used, for example, as an antidepressant.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU74471/00A AU763502B2 (en) | 1999-11-24 | 2000-09-28 | Anhydrous mirtazapine crystals and process for the production thereof |
JP2001540093A JP3699680B2 (ja) | 1999-11-24 | 2000-09-28 | 無水ミルタザピン結晶およびその製造方法 |
DK00962908T DK1225174T3 (da) | 1999-11-24 | 2000-09-28 | Vandfri mirtazapinkrystaller og fremgangsmåde til fremstilling deraf |
CA002370376A CA2370376C (en) | 1999-11-24 | 2000-09-28 | Anhydrous mirtazapine crystals and process for the production thereof |
AT00962908T ATE261966T1 (de) | 1999-11-24 | 2000-09-28 | Wasserfreie mirtazapin-kristalle und ein verfahren zu ihrer herstellung |
EP00962908A EP1225174B2 (en) | 1999-11-24 | 2000-09-28 | Anhydrous mirtazapine crystals and process for the production thereof |
DE60009117T DE60009117T2 (de) | 1999-11-24 | 2000-09-28 | Wasserfreie mirtazapin-kristalle und ein verfahren zu ihrer herstellung |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP33304999 | 1999-11-24 | ||
JP11/333049 | 1999-11-24 | ||
JP2000-67476 | 2000-03-10 | ||
JP2000067476 | 2000-03-10 | ||
JPPCT/JP00/04835 | 2000-07-19 | ||
PCT/JP2000/004835 WO2001038329A1 (fr) | 1999-11-24 | 2000-07-19 | Cristaux de mirtazapine anhydre et leur procede d'obtention |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2001038330A1 true WO2001038330A1 (fr) | 2001-05-31 |
Family
ID=26574376
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2000/004835 WO2001038329A1 (fr) | 1999-11-24 | 2000-07-19 | Cristaux de mirtazapine anhydre et leur procede d'obtention |
PCT/JP2000/006687 WO2001038330A1 (fr) | 1999-11-24 | 2000-09-28 | Cristaux de mirtazapine anhydres et leur procede de fabrication |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2000/004835 WO2001038329A1 (fr) | 1999-11-24 | 2000-07-19 | Cristaux de mirtazapine anhydre et leur procede d'obtention |
Country Status (11)
Country | Link |
---|---|
US (3) | US6552189B2 (ja) |
EP (1) | EP1225174B2 (ja) |
JP (1) | JP3699680B2 (ja) |
AT (1) | ATE261966T1 (ja) |
AU (2) | AU6019900A (ja) |
CA (1) | CA2370376C (ja) |
DE (1) | DE60009117T2 (ja) |
DK (1) | DK1225174T3 (ja) |
ES (1) | ES2214318T5 (ja) |
PT (1) | PT1225174E (ja) |
WO (2) | WO2001038329A1 (ja) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005051925A1 (ja) * | 2003-11-27 | 2005-06-09 | Ajinomoto Co., Inc. | フェニルアラニン誘導体の結晶及びその製造方法 |
WO2008114691A1 (ja) | 2007-03-22 | 2008-09-25 | Sumitomo Chemical Company, Limited | ミルタザピンの製造方法 |
JP2017039659A (ja) * | 2015-08-19 | 2017-02-23 | 株式会社トクヤマ | ミルタザピンの製造方法 |
JP2017088564A (ja) * | 2015-11-13 | 2017-05-25 | 株式会社トクヤマ | ミルタザピンの製造方法 |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001038329A1 (fr) * | 1999-11-24 | 2001-05-31 | Sumika Fine Chemicals Co., Ltd. | Cristaux de mirtazapine anhydre et leur procede d'obtention |
US7838029B1 (en) * | 2003-07-31 | 2010-11-23 | Watson Laboratories, Inc. | Mirtazapine solid dosage forms |
EP1689371A2 (en) * | 2003-11-25 | 2006-08-16 | Aurobindo Pharma Limited | Pharmaceutical compositions of mirtazapine |
US20060039866A1 (en) * | 2004-08-20 | 2006-02-23 | Cypress Bioscience, Inc. | Method for treating sleep-related breathing disorders |
CN101855401B (zh) * | 2007-04-05 | 2013-01-02 | 阿克佐诺贝尔股份有限公司 | 提高纸的光学性能的方法 |
CA2704117C (en) * | 2007-11-02 | 2015-11-17 | Acrux Dds Pty Ltd | Transdermal delivery system |
CN103520169B (zh) * | 2013-10-25 | 2015-07-15 | 山东鲁药制药有限公司 | 米氮平片及其制备方法 |
DK3261645T3 (da) | 2015-02-27 | 2021-06-07 | Dechra Ltd | Stimulering af appetit, håndtering af vægttab og behandling af anoreksi hos hunde og katte |
JP6571497B2 (ja) * | 2015-11-13 | 2019-09-04 | 株式会社トクヤマ | ミルタザピンの製造方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4062848A (en) * | 1975-04-05 | 1977-12-13 | Akzona Incorporated | Tetracyclic compounds |
JPH07247286A (ja) * | 1994-01-18 | 1995-09-26 | Sankyo Co Ltd | 含窒素環状化合物の光学分割方法 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4524146A (en) | 1982-12-08 | 1985-06-18 | Ciba-Geigy Corporation | Certain -2-heterocycle substituted pyrazoloquinolines |
NZ230711A (en) | 1988-09-23 | 1990-10-26 | Ortho Pharma Corp | Substituted thienopyrans as antihypertensive agents |
US5354763A (en) | 1993-11-17 | 1994-10-11 | American Home Products Corporation | Substituted N-heteroaryl and N-aryl-1,2-diaminocyclobutene-3,4-diones |
US5468768A (en) | 1994-01-06 | 1995-11-21 | Bristol-Myers Squibb Company | Antimigraine derivatives of indolylcycloalkanylamines |
US6545149B2 (en) | 1999-04-19 | 2003-04-08 | Teva Pharmaceutical Industries Ltd. | Synthesis and crystallization of piperazine ring-containing compounds |
SK14672001A3 (sk) * | 1999-04-19 | 2002-11-06 | Teva Pharmaceutical Industries Ltd. | Spôsob syntézy a kryštalizácie zlúčenín obsahujúcich piperazínový kruh |
WO2001038329A1 (fr) * | 1999-11-24 | 2001-05-31 | Sumika Fine Chemicals Co., Ltd. | Cristaux de mirtazapine anhydre et leur procede d'obtention |
US20020072602A1 (en) | 2000-07-07 | 2002-06-13 | Claude Singer | Micronized mirtazapine |
US6660730B2 (en) * | 2000-11-27 | 2003-12-09 | Sumika Fine Chemicals Co., Ltd. | Anhydrous mirtazapine and process for preparing the same |
-
2000
- 2000-07-19 WO PCT/JP2000/004835 patent/WO2001038329A1/ja active Application Filing
- 2000-07-19 AU AU60199/00A patent/AU6019900A/en not_active Abandoned
- 2000-09-28 AT AT00962908T patent/ATE261966T1/de not_active IP Right Cessation
- 2000-09-28 ES ES00962908T patent/ES2214318T5/es not_active Expired - Lifetime
- 2000-09-28 WO PCT/JP2000/006687 patent/WO2001038330A1/ja active IP Right Grant
- 2000-09-28 PT PT00962908T patent/PT1225174E/pt unknown
- 2000-09-28 AU AU74471/00A patent/AU763502B2/en not_active Ceased
- 2000-09-28 DK DK00962908T patent/DK1225174T3/da active
- 2000-09-28 DE DE60009117T patent/DE60009117T2/de not_active Expired - Lifetime
- 2000-09-28 EP EP00962908A patent/EP1225174B2/en not_active Expired - Lifetime
- 2000-09-28 CA CA002370376A patent/CA2370376C/en not_active Expired - Fee Related
- 2000-09-28 JP JP2001540093A patent/JP3699680B2/ja not_active Expired - Lifetime
-
2002
- 2002-01-10 US US10/041,495 patent/US6552189B2/en not_active Expired - Fee Related
-
2003
- 2003-01-07 US US10/337,277 patent/US6723845B2/en not_active Expired - Fee Related
- 2003-12-24 US US10/743,740 patent/US7297790B2/en not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4062848A (en) * | 1975-04-05 | 1977-12-13 | Akzona Incorporated | Tetracyclic compounds |
JPH07247286A (ja) * | 1994-01-18 | 1995-09-26 | Sankyo Co Ltd | 含窒素環状化合物の光学分割方法 |
Non-Patent Citations (1)
Title |
---|
TOMORI H. ET AL.: "Facile optical resolution of a dibenzopyrazinoazepine derivative and the nature of molecular recognition of amines by chiral 2,3-di-O-(arylcarbonyl)tartaric acids", BULL. CHEM. SOC. JPN., vol. 69, no. 12, 1996, pages 3581 - 3590, XP002935497 * |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005051925A1 (ja) * | 2003-11-27 | 2005-06-09 | Ajinomoto Co., Inc. | フェニルアラニン誘導体の結晶及びその製造方法 |
US7683169B2 (en) | 2003-11-27 | 2010-03-23 | Ajinomoto Co., Inc. | Crystals of phenylalanine derivatives and production methods thereof |
US7951942B2 (en) | 2003-11-27 | 2011-05-31 | Ajinomoto Co., Inc. | Crystals of phenylalanine derivatives and production methods thereof |
WO2008114691A1 (ja) | 2007-03-22 | 2008-09-25 | Sumitomo Chemical Company, Limited | ミルタザピンの製造方法 |
JP2008231062A (ja) * | 2007-03-22 | 2008-10-02 | Sumitomo Chemical Co Ltd | ミルタザピンの製造方法 |
CN101541798B (zh) * | 2007-03-22 | 2011-09-14 | 住友化学株式会社 | 米氮平的制造方法 |
US8173804B2 (en) | 2007-03-22 | 2012-05-08 | Sumitomo Chemical Company, Limited | Process for production of mirtazapine |
KR101418620B1 (ko) | 2007-03-22 | 2014-07-14 | 스미또모 가가꾸 가부시키가이샤 | 미르타자핀의 제조 방법 |
JP2017039659A (ja) * | 2015-08-19 | 2017-02-23 | 株式会社トクヤマ | ミルタザピンの製造方法 |
JP2017088564A (ja) * | 2015-11-13 | 2017-05-25 | 株式会社トクヤマ | ミルタザピンの製造方法 |
Also Published As
Publication number | Publication date |
---|---|
CA2370376C (en) | 2005-08-02 |
AU7447100A (en) | 2001-06-04 |
US20030130504A1 (en) | 2003-07-10 |
ES2214318T5 (es) | 2010-10-15 |
DE60009117T2 (de) | 2004-10-21 |
EP1225174A4 (en) | 2002-10-23 |
US20040138447A1 (en) | 2004-07-15 |
WO2001038329A1 (fr) | 2001-05-31 |
PT1225174E (pt) | 2004-05-31 |
US6723845B2 (en) | 2004-04-20 |
EP1225174B1 (en) | 2004-03-17 |
DK1225174T3 (da) | 2004-07-05 |
US6552189B2 (en) | 2003-04-22 |
AU763502B2 (en) | 2003-07-24 |
US7297790B2 (en) | 2007-11-20 |
ES2214318T3 (es) | 2004-09-16 |
CA2370376A1 (en) | 2001-05-31 |
ATE261966T1 (de) | 2004-04-15 |
US20020103372A1 (en) | 2002-08-01 |
JP3699680B2 (ja) | 2005-09-28 |
EP1225174A1 (en) | 2002-07-24 |
EP1225174B2 (en) | 2010-06-02 |
AU6019900A (en) | 2001-06-04 |
DE60009117D1 (de) | 2004-04-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2001038330A1 (fr) | Cristaux de mirtazapine anhydres et leur procede de fabrication | |
US20100183877A1 (en) | Magnesium oxide particle aggregate and method for producing the same | |
JP5836472B2 (ja) | 結晶性酸化セリウム及びその製造方法 | |
US20160043433A1 (en) | Glass particles | |
EP3533761A1 (en) | Surface-modified halloysite, method for producing surface-modified halloysite, and catalytic reaction | |
TW201945286A (zh) | 碳酸鋇之製造方法 | |
US9920005B2 (en) | Method for crystallization of 2-amino-2-[2-[4-(3-benzyloxyphenylthio)-2-chlorophenyl]ethyl]-1,3-propanediol hydrochloride | |
JP3958948B2 (ja) | ポリエステル原料の製造方法 | |
WO2017167949A1 (en) | Crystalline forms of bilastine | |
JP6124562B2 (ja) | 4′−[[2−n−プロピル−4−メチル−6−(1−メチルベンズイミダゾール−2−イル)−ベンズイミダゾール−1−イル]−メチル]−ビフェニル−2−カルボン酸のアンモニウム塩の結晶 | |
JP7177796B2 (ja) | アジルサルタンa型結晶の製造方法 | |
EP4349777A1 (en) | Method for preparing sulfide-based solid electrolyte | |
US20110015413A1 (en) | Process for preparing crystalline calcium mupirocin dihydrate | |
WO2020090948A1 (ja) | Cyclic-di-AMPナトリウム塩結晶 | |
US20110218339A1 (en) | Crystalline polymorph of biopterin and production method thereof | |
JP5448588B2 (ja) | L−カルノシンの精製方法 | |
JP2011173752A (ja) | 酸化ジルコニウム粒子およびその製造方法 | |
JP2018508515A (ja) | 固形結晶形体4−(2−メチル−1h−イミダゾール−1−イル)−2,2−ジフェニルブタンニトリル | |
WO1997001563A1 (fr) | Cristaux de benzoates bicozamycine stables | |
JP2009067695A (ja) | ビオプテリンの結晶多形、及びそれらの製造方法 | |
JP2014034521A (ja) | ミチグリニドカルシウム水和物の結晶を製造する方法 | |
JP2010260826A (ja) | パロキセチン塩酸塩半水和物の製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ENP | Entry into the national phase |
Ref country code: US Ref document number: 2000 697329 Date of ref document: 20001027 Kind code of ref document: A Format of ref document f/p: F |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA IN JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2001 540093 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 74471/00 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2370376 Country of ref document: CA Ref country code: CA Ref document number: 2370376 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000962908 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2000962908 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 2000962908 Country of ref document: EP |